These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 35273962)

  • 1. Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC.
    Cattolico C; Bailey P; Barry ST
    Front Cell Dev Biol; 2022; 10():816517. PubMed ID: 35273962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?
    Narayanan S; Vicent S; Ponz-Sarvisé M
    Front Cell Dev Biol; 2021; 9():787249. PubMed ID: 34957115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle delivery of innate immune agonists combines with senescence-inducing agents to mediate T cell control of pancreatic cancer.
    Chibaya L; Lusi CF; DeMarco KD; Kane GI; Brassil ML; Parikh CN; Murphy KC; Li J; Naylor TE; Cerrutti J; Peura J; Pitarresi JR; Zhu LJ; Fitzgerald KA; Atukorale PU; Ruscetti M
    bioRxiv; 2023 Sep; ():. PubMed ID: 37790484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
    J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
    Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
    Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIN3B Loss Heats up Cold Tumor Microenvironment to Boost Immunotherapy in Pancreatic Cancer.
    Zhang Z; Tang Y; Wang Y; Xu J; Yang X; Liu M; Mazzone M; Niu N; Sun Y; Tang Y; Xue J
    Adv Sci (Weinh); 2024 Nov; 11(43):e2402244. PubMed ID: 39316363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
    Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
    Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.
    Romero JM; Grünwald B; Jang GH; Bavi PP; Jhaveri A; Masoomian M; Fischer SE; Zhang A; Denroche RE; Lungu IM; De Luca A; Bartlett JMS; Xu J; Li N; Dhaliwal S; Liang SB; Chadwick D; Vyas F; Bronsert P; Khokha R; McGaha TL; Notta F; Ohashi PS; Done SJ; O'Kane GM; Wilson JM; Knox JJ; Connor A; Wang Y; Zogopoulos G; Gallinger S
    Clin Cancer Res; 2020 Apr; 26(8):1997-2010. PubMed ID: 31964786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PLA2G2A
    Ge W; Yue M; Lin R; Zhou T; Xu H; Wang Y; Mao T; Li S; Wu X; Zhang X; Wang Y; Ma J; Wang Y; Xue S; Shentu D; Cui J; Wang L
    Cancer Lett; 2023 Apr; 558():216095. PubMed ID: 36796670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote the immunotherapy of pancreatic cancer.
    Wang R; Hong K; Zhang Q; Cao J; Huang T; Xiao Z; Wang Y; Shuai X
    Acta Biomater; 2023 Oct; 169():451-463. PubMed ID: 37572982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.
    Alzhrani R; Alsaab HO; Vanamal K; Bhise K; Tatiparti K; Barari A; Sau S; Iyer AK
    Adv Ther (Weinh); 2021 Jun; 4(6):. PubMed ID: 34212073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
    Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S
    Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.
    Kumar S; Singh SK; Srivastava P; Suresh S; Rana B; Rana A
    Adv Cancer Res; 2023; 159():113-143. PubMed ID: 37268394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma.
    Lekan AA; Weiner LM
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.